Background: Leptomeningeal carcinomatosis is a relatively rare metastatic form of non-small cell lung cancer, which can impact prognosis. There is an increasing need for selecting suitable epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors among those currently included in standard care for EGFR mutation-positive patients. We compared the efficacy of gefitinib and erlotinib in survival of patients with leptomeningeal carcinomatosis. Patients and methods: The medical records of 269 patients who received tyrosine kinase inhibitors at a single center were retrospectively reviewed. Overall, 22 patients (8.2%) were treated with tyrosine kinase inhibitors for leptomeningeal carcinomatosis from non-small cell lung cancer with EGFR mutation between 2006 and 2016. Time to death from leptomeningeal carcinomatosis diagnosis was compared between the gefitinib and erlotinib groups. Results: Gefitinib and erlotinib were administrated to 5 and 17 patients, respectively. Median progression-free survival was longer in the erlotinib group than in the gefitinib group (6.60 vs 2.12 months, P = 0.07). Overall survival was more than twice as long in the erlotinib arm compared with that in the gefitinib arm (7.20 vs 2.99 months, P = 0.32). Response in patients with exon 19 deletion was better than in those with exon 21 mutation (overall survival, 7.20 and 5.62 months, respectively, P = 0.12). Conclusions: Erlotinib seemed more effective than gefitinib in prolonging survival in leptomeningeal carcinomatosis from EGFR mutation-positive non-small cell lung cancer and may be particularly beneficial in patients with EGFR exon 19 mutations, warranting further studies.
Introduction
Leptomeningeal carcinomatosis (LMC), observed in 5% of patients with non-small cell lung cancer (NSCLC), is increasing in incidence owing to the longer survival of patients enabled by recently developed systemic therapies (1) . As the number of LMC patients among those with NSCLC was relatively low, previous studies usually combined NSCLC cases with LMC and those with brain metastases (BM) under the definition of central nervous system (CNS) metastases, although distinct approaches were used for LMC and BM treatment. While BM can be treated by either surgery or radiological interventions in certain patients with localized disease, treatment options for LMC include tyrosine kinase inhibitors (TKIs), cytotoxic chemotherapies, whole brain radiotherapy (WBRT) and intrathecal therapy. WBRT alone is reported to be ineffective, particularly in NSCLC patients (2) ; therefore, combinations of these modalities are usually considered for LMC in patients with NSCLC. Gefitinib and erlotinib, both among the first generation of epidermal growth factor receptor (EGFR) TKIs, are associated with favorable responses more frequently in patients harboring exon 19 deletion or point mutation at codon L858 to R in exon 21 of EGFR (3). Penetration of the blood-brain barrier is a major clinical problem during administration of systemic therapy for intracranial metastases; however, in retrospective studies, EGFR TKIs were also effective in their treatment. Specifically, erlotinib reportedly reached higher concentrations than gefitinib in the cerebrospinal fluid (4) . Despite reports of several LMC cases showing drastic improvement with EGFR TKIs (5) (6) (7) (8) , studies comparing the clinical efficacy of EGFR TKIs in LMC are lacking.
A previous retrospective study showed that the control rate of LMC, determined by cytology of cerebrospinal fluid, was higher with erlotinib than gefitinib and that the overall survival (OS) of patients treated with erlotinib was twice as long as those treated with gefitinib, although this difference was not statistically significant (9) . While a recent study found that TKIs and cytotoxic chemotherapy were among the prognostic factors in patients with LMC harboring EGFR mutations (10), strong evidence for the efficacy of TKI in LMC is lacking. LMC patients with EGFR exon 19 deletions reportedly respond to TKI therapy better than do those with exon 21 point mutations (11) ; however, the relationship between TKI efficacy and EGFR mutation status remains unknown.
In this study, we retrospectively analyzed the efficacy of two EGFR TKIs, erlotinib and gefitinib, by determining the survival of patients treated at a single center for LMC from NSCLC.
Patients and methods

Data acquisition
A total of 269 advanced or recurrent NSCLC patients who were treated with EGFR TKIs at any stage of the clinical course at Tokyo Metropolitan Cancer and Infectious disease Center Komagome Hospital were identified from the electrical medical database (Fig. 1) . A total of 31 patients developed LMC during follow-up. Four patients with LMC who were either treated with TKIs before LMC diagnosis or did not receive any TKIs after LMC diagnosis were excluded. Thus, 27 patients with LMC from NSCLC were treated with TKIs after the diagnosis of LMC. Among these, 22 patients were genetically diagnosed to harbor EGFR mutations (see Section 2.2) and they were included in the final analysis. Diagnosis of LMC was made in August 2006 and February 2016. Eight of these patients were diagnosed by cytology of the cerebrospinal fluid; the remaining 14 patients were diagnosed by computed tomography (CT) or magnetic resonance imaging (MRI). Gefitinib was administrated to five patients; 17 patients received erlotinib after LMC diagnosis. Type of TKI was determined by the attending physicians, and, if needed, TKI dose (erlotinib, 150 mg/d; gefitinib, 250 mg/d) was reduced based on the clinical condition of patients. Seven of a total of 22 patients received the same TKI from therapy initiation at the time of LMC diagnosis until the end of the observational period; 11 patients were switched from another TKI to the current TKI owing to LMC diagnosis.
This study was approved by the institutional review committee of Tokyo Metropolitan Cancer and Infectious disease Center Komagome Hospital.
EGFR mutation analysis
EGFR mutations in biopsy specimens or bronchoalveolar lavage fluid from patients were determined by a commercial central laboratory at SRL (Tokyo, Japan). Beginning on June 1, 2007, outsourcing of EGFR genetic testing was covered by government insurance in Japan. Screening was performed by direct sequencing, peptide nucleic acid-locked nucleic acid polymerase chain reaction (PCR) clamp method (12) or PCR-invader assay (13) . Specimens were screened for exon 19 deletion and L858R point mutations. Exon 20 T790M mutation of EGFR is correlated with resistance to EGFR TKIs; therefore, patients harboring exon 20 T790M were not treated with EGFR TKIs (14) and were excluded from the present study.
Statistical analysis
Descriptive statistics were used to summarize baseline characteristics of the patients. Progression-free survival (PFS) was defined as the time from the initiation of EGFR TKI to the date of disease progression confirmed by CT or MRI or progression of syndrome derived from LMC. OS was defined as the time from the date of TKI therapy initiation after LMC diagnosis to the date of death from any cause. Cases in which EGFR TKI therapy was terminated owing to toxicity, development of oral intolerance, and patient refusal, were excluded.
Categorical variables were compared using Pearson's chi-square test or Fisher's exact test. Log-rank test was performed to compare PFS and OS estimated by the Kaplan-Meier method. Two-sided P values of < 0.05 were considered statistically significant. All statistical analyses were performed using R version 3. 
Results
Patient characteristics
The baseline characteristics of 22 patients with LMC from EGFR mutation-positive NSCLC are presented in Table 1 . Erlotinib was administrated to 17 patients as the initial TKI therapy, whereas five patients received gefitinib. Median age at the time of LMC diagnosis was 61 (range: 43-76) years in the erlotinib arm and 64 (range: 54-71) years in the gefitinib arm. Exon 21 point mutation and exon 19 deletion of EGFR gene were observed in 10 and 7 patients, respectively, in the erlotinib arm, and in two patients each, in the gefitinib arm. In the erlotinib arm, 14 patients were initiated on erlotinib after LMC diagnosis; three patients receiving erlotinib before LMC diagnosis continued on the same regimen following diagnosis. In the gefitinib arm, one patient was initiated on gefitinib after LMC diagnosis; four patients treated with gefitinib before LMC diagnosis continued on the same regimen following diagnosis. Five patients in the erlotinib arm and one patient in the gefitinib arm were lost to follow-up within the first 3 months after LMC diagnosis owing to transfer of patients to palliative care. Eight and four patients are suspected to have died because of LMC in erotinib and gefitinib groups, respectively. Neurological symptoms are also described in Table 1 , Common symptoms were nausea, headache, and consciousness alternation. Improvement in neurological symptoms was observed in seven patients in erlotinib arm, whereas those of the four patients in the gefitinib arm progressed. Figure 2 shows the swimmers plot of patients included in this study.
Survival analysis
Median PFS was longer in the erlotinib group than in the gefitinib group (6.60 vs 2.12 months, Fig. 3A) . Median OS, defined as the interval from the date of TKI therapy initiation after LMC diagnosis to the date of death from any cause, was more than twice as long in the erlotinib arm than in the gefitinib arm (7.20 vs 2.99 months, respectively, Fig. 3B ); this was not significantly different (P = 0.32). However, similar to that observed in OS rates, the difference in PFS was not statistically significant (P = 0.07).
Comparison of median OS between patients harboring exon 19 deletion (n = 9) and those harboring exon 21 mutation (n = 12) revealed difference of 1.6 months (7.20 vs 5.62 months, respectively); however, this was not statistically significant (P = 0.12).
Discussion
Third-generation EGFR TKIs, which are indicated in overcoming acquired resistance to earlier generation EGFR TKIs, and biomarkers to identify select TKI responders are now available (15) . Patients with CNS metastases, particularly those with LMC, are the most challenging to biopsy for diagnosis. In addition, CNS metastases occasionally deteriorate the performance status of patients owing to fatigue (16) , and hinder oral administration of TKIs. Therefore, prevention and control of CNS metastases garnered increased interest in the era of new-generation TKIs. Previous studies demonstrated that disease progression in CNS was relatively rare (as high as 2.9-8.0%, reviewed in Table 2 ) in patients treated with erlotinib (17) (18) (19) . Although it was not statistically significant, our findings also demonstrated that the PFS was longer in the erlotinib group (6.60 months). Moreover, neurological symptoms were improved in seven patients (41%) in the erlotinib arm, whereas symptom progression was observed in four patients (80%) in the gefitinib arm. Several case reports and series found that erlotinib was associated with improved neurological symptoms in patients with brain metastases previously treated with gefitinib (20, 21) .We have recently reported that erlotinib had longer brain metastasis control period (22) . Thus, erlotinib might play an important role in the prevention and control of disease in patients with CNS metastases.
In this retrospective study, we found that the median OS of patients treated with erlotinib as first TKI after LMC diagnosis seemed much longer than that observed with gefitinib, though the difference was not statistically significant. This finding was consistent with that of a previous study on NSCLC patients (9) . We should interpret the result with caution. Four patients (80%) in the gefitinib group were treated with TKI beyond progression in comparison to three patients (17.6%) in the erlotinib group. While the survival benefit of erlotinib might have been overestimated by this unbalanced background of patients, the result may indicate the superiority of erlotinib in prolonging survival of patients with LMC.
Our finding implying that the median OS of patients with EGFR exon 19 deletion was longer than that of patients with exon 21 mutation was consistent with a previous study of NSCLC patients in Japan (11) . A recent meta-analysis also demonstrated the favorable survival of patients with exon 19 deletion following EGFR TKI treatment (23) . Our result thus might reflect the efficacy of TKI treatment especially in patients with exon 19 deletion, which should be confirmed by future studies because the sample size of the presented study was quite small.
The benefit of erlotinib observed in our sole patient suggested that erlotinib might be effective in cases where gefitinib might fail to control LMC, as implicated in previous case reports (20, 21) . Development of secondary mutations in EGFR, such as T790M, which can lead to TKI resistance (24) , cannot be avoided during TKI treatment. Ohara et al. (25) reported a patient whose primary lesion acquired the T790M mutation after gefitinib therapy and whose brain metastatic lesion discovered after the first TKI treatment was negative for T790M. Another study reported that erlotinib concentrations were significantly higher than gefitinib levels in the cerebrospinal fluid and that a patient with LMC who was refractory to gefitinib showed a dramatic and favorable response to erlotinib (4). Findings of these earlier studies, together with our results, suggest that switching to erlotinib might extend the survival of patients with LMC.
The limitations of our study need to be addressed. First, the number of patients who enrolled in this retrospective study was small so we could not find any statistically significant differences and we could not rule out selection bias. Additionally, the choice of TKI for treatment depended on the attending physician. Second, TKI dose was adjusted and reduced according to the performance status of patients, and the efficacy of TKIs might have been underestimated.
Conclusion
In this retrospective study, the median PFS and OS of patients with LMC from NSCLC treated with erlotinib seemed 2-and 3-fold as long as that of patients treated with gefitinib, respectively, although these differences were not statistically significant. Patients' background was not balanced in the presented study; therefore, further cases need to be studied to evaluate the superiority of effectiveness against LMC between two TKIs.
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